Printer Friendly

ENDOTRONICS, INC. RECEIVES $1 MILLION PURSUANT TO INVESTMENT AGREEMENT WITH INTEGRA HOLDING AG OF SWITZERLAND

 ENDOTRONICS, INC. RECEIVES $1 MILLION PURSUANT TO
 INVESTMENT AGREEMENT WITH INTEGRA HOLDING AG OF SWITZERLAND
 MINNEAPOLIS, Feb. 26 /PRNewswire/ -- Endotronics, Inc. (NASDAQ: ENDO) today announced it has received approximately $1 million pursuant to an exercise of warrants by INTEGRA Holding AG of Switzerland.
 In February 1991, Endotronics and INTEGRA entered into an agreement which provided for a $2 million investment by INTEGRA; a European-wide distribution agreement with Tecnomara AG, a Swiss subsidiary of INTEGRA; and a cooperative research and development agreement with Tecnomara GmbH, a German subsidiary of INTEGRA. Pursuant to that agreement, Endotronics issued warrants to INTEGRA for the purchase of 4 million shares of Endotronics common stock at an exercise price of $.75 per common share, exercisable during the six-year period following issuance.
 "We view this infusion of capital as extremely positive, and indicative of the solidification of our relationship with INTEGRA and their confidence in our strategy," said Richard E. Sakowicz, president and chief operating officer of Endotronics. "It is clear to us that our initial cooperative effort to develop a new research instrument is meeting with success. The recently announced ACUMOUSE(TM) is expected to lead to other exciting projects with INTEGRA Biosciences which take advantage of the strengths of our two companies."
 Endotronics, Inc., headquartered in Minneapolis, is dedicated to providing cell processing products and services to meet the needs of human health care and biotechnology markets worldwide. The company is a recognized leader in hollow fiber cell culture instrumentation with more than 675 instruments installed worldwide.
 -0- 2/26/92
 /CONTACT: Yvonne L. Marschner-Bova of Endotronics, 313-871-7350/
 (ENDO) CO: Endotronics, Inc. ST: Minnesota IN: MTC SU: FNC


ML -- DE010 -- 2761 02/26/92 11:24 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 26, 1992
Words:282
Previous Article:BROOKLYN UNION GAS CALLS PREFERRED STOCK FOR REDEMPTION
Next Article:HYPERION CAPITAL MANAGEMENT ANNOUNCES NEW PRESIDENT AND CEO
Topics:


Related Articles
ENDOTRONICS, INC. INTRODUCES ACUMOUSE CELL CULTURE INSTRUMENT -- COST-EFFECTIVE SUBSTITUTE FOR LABORATORY MICE
UNIVERSITY OF MINNESOTA AND ENDOTRONICS, INC. TO COLLABORATE ON DEVELOPMENT OF BIO-ARTIFICIAL DEVICE TO REPLACE LIVER FUNCTION
ENDOTRONICS DISCONTINUES DISTRIBUTION AGREEMENT WITH VENTREX LABORATORIES -- SIGNS LETTER OF INTENT WITH NORTHUMBRIA BIOLOGICALS
ENDOTRONICS, INC. RECEIVES U.S. PATENT ON SCALABLE OXYCELL CELL CULTURE TECHNOLOGY
ENDOTRONICS, INC. REPORTS RESULTS FOR FIRST QUARTER ENDED DEC. 31, 1991
ENDOTRONICS SIGNS PRODUCTION AND MARKETING AGREEMENT WITH HELIXYS
ENDOTRONICS, INC. AGREES TO PURCHASE VERAX PRODUCT LINE

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters